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Diet is well known to have beneficial health properties that extend beyond traditionally accepted nutritional effects. The approach
involved in elucidating these beneficial physiological effects is becoming more important, as reflected by increasing research being under-
taken. With growing consumer awareness of foods and food constituents and their relationship to health, the key questions for regulators,
scientists and the food industry continue to relate to: (1) how consumers could be protected and have confidence that the health claims on
foods are well supported by the evidence; (2) how research on physiological effects of food (constituents) and their health benefits could
be stimulated and supported; (3) how research findings could be used in the development of innovative new food products. The objectives
of this paper are to provide a set of recommendations on the substantiation of health claims for foods, to develop further guidance on the
choice of validated markers (or marker patterns) and what effects are considered to be beneficial to the health of the general public
(or specific target groups). Finally, the case for developing a standardised approach for assessing the totality of the available scientific
data and weighing the evidence is proposed.
The importance of developing a standardised evidence-based
approach for establishing food–health relationships has been
addressed previously by the ‘Process for the Assessment of
Scientific Support for CLAIMs on foods’ (PASSCLAIM)(1).
Following exchanges across industry, regulators and acade-
mia(2), the objective of this paper was to provide a set of
recommendations on the scientific substantiation of health
claims for foods, to develop further guidance on the choice
of validated (generally accepted) markers (or marker patterns)
and on what effects are considered to be beneficial to the
health of the general public (or specific target groups). (The
current paper focuses on food and food constituents with
health benefits that are aimed at the generally healthy popu-
lation. Clinical nutrition meets the particular nutritional
requirements of individuals affected by, or who are malnour-
ished due to, a specific disease or condition. Communication
on these specific benefits is not regulated under the European
Nutrition and Health Claim Regulation. For this reason, clinical
nutrition is outside the scope of this publication.)
General approaches to claim substantiation
Health claim definitions and regulatory frameworks
Although definitions of health claims are slightly different
around the world (e.g. European Parliament and Council(3);
US Food and Drug Administration (FDA)(4); Codex Alimentar-
ius(5)), usually a distinction is made between ‘nutrient
function’ claims, ‘other function’ or ‘enhanced function’
claims and ‘reduction of disease risk’ claims. For instance, in
the European Union, a ‘health claim’ is any claim that states,
suggests or implies that a relationship exists between a food
category, a food or one of its constituents and health.
A ‘reduction of disease risk’ claim is defined as any health
claim that states, suggests or implies that the consumption of
a food category, a food or one of its constituents significantly
reduces a risk factor in the development of a human disease.
Claims that do not refer to disease risk reduction relate to
a positive contribution to health, to the improvement of a
function or to preserving health. Codex alimentarius defines
that a ‘nutrient function’ claim describes the role of a nutrient
intended to affect normal body structure or function(5). An
‘other function’ claim (or ‘enhanced function’ claim) is defined
as a claim concerning a specific beneficial effect of the
consumption of foods or their constituents (not including
nutrients), in the context of the total diet, on a physiological
function or biological activity(5).
The aim of regulatory frameworks in different regions of the
world is to ensure confidence in health claims on foods by
requiring that all authorised claims are scientifically substan-
tiated, and thereby to promote innovation and to achieve a
high degree of consumer protection.
In Europe, regulation 1924/2006 applies to nutrition and
health claims made in commercial communications and sets
out the conditions for their use, establishes a system of scien-
tific evaluation and creates European Community lists of
authorised claims(3). It requires that the claims are based on
‘generally accepted scientific evidence’ and that they are
well understood by the ‘average consumer’.
The European Food Safety Authority (EFSA) Panel on Diete-
tic Products, Nutrition and Allergies assesses health claims
under Article 13.1 (‘general function’ health claims), Article
13.5 (‘new function’ health claims, based on newly developed
scientific evidence and/or that include a request for protection
of proprietary data) or Article 14 (‘reduction of disease risk’
claims and claims referring to children’s development and
health). Here, the scope of ‘function claims’ includes the
‘role of a nutrient or other substance in growth, development
and the functions of the body, psychological and behavioural
functions or without prejudice to Directive 96/8/EC, slimming
or weight control or a reduction in the sense of hunger or
an increase in the sense of satiety or to the reduction of the
available energy from the diet’(3). EFSA publishes scientific
opinions on all types of claims(6). Once accepted, (general)
claims can be made without undergoing any further authoris-
ation procedure. From the series of opinions published thus
far(6), much can be learned about EFSA’s line of thinking,
for instance, on what type of effects are considered to be
relevant to human health, what type of studies are considered
to be pertinent to the health claim and how the quality of
studies is judged. These issues are addressed in this paper.
Outside Europe, the regulatory landscape differs slightly. In
the United States ‘reduction of disease risk’ claims have been
allowed on certain foods since 1993. These foods contain
components for which the FDA has accepted that for a corre-
lation between nutrients or foods in the diet and risk of certain
diseases, based on ‘the totality of publicly available scientific
evidence’, there is substantial agreement amongst qualified
experts that claims were supported by the evidence(7–9).
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The highest level of health claims in the United States are
‘unqualified’ health claims that confirm relationships between
components in the diet and risk of disease or a health con-
dition that are based on significant scientific agreement.
Health claims can also be based on authoritative statements
(resulting from a scientific body of the US Government or
the National Academy of Science), and are permitted follow-
ing notification to FDA and FDA’s subsequent failure to
object. Another category of health claims concerns so-called
‘qualified’ health claims that are used for describing develop-
ing relationships between components in the diet and disease.
Such claims require qualifying language such as ‘although
there is scientific evidence supporting the claim, the evidence
is not conclusive’ and these claims require pre-market
approval of the FDA. The FDA has published a list of
approved unqualified claims(10) and overviews of qualified
health claims that have been approved(11) or denied(12). In
addition to approved FDA disease risk reduction claims,
structure function claims are permitted on foods and dietary
supplements. Structure function claims describe the role of a
nutrient or dietary ingredient intended to affect normal struc-
ture or function in human subjects(13). Structure function
claims are not pre-approved by FDA, but must be truthful
and must not be misleading. It is clearly recognised
that, worldwide, health claims need to be scientifically
substantiated.
Criteria for the scientific substantiation of health claims
Worldwide, there is broad consensus among scientists on the
PASSCLAIM criteria for the scientific substantiation of health
claims(1). These criteria aimed to provide a scientifically
robust tool for evaluating the quality of data submitted in
support of health claims for foods and to provide a standard
against which the quality of existing evidence can be transpar-
ently graded.
In different regions of the world, regulatory bodies have
published guidelines for manufacturers who want to apply
for approval of certain health claims. These guidelines are
broadly in accordance with the PASSCLAIM criteria. Current
guidelines from international regulatory bodies can be sum-
marised as follows:
(1) Applications for the authorisation of health claims should
adequately demonstrate that the health claim is based on
and substantiated by generally accepted scientific
evidence, by taking into account the totality of the avail-
able scientific data and by weighing the evidence.
(2) A prerequisite of claim submission dossiers is a proper
characterisation of the food or the food constituent,
including composition, physical and chemical character-
istics, manufacturing process, stability and (where appli-
cable) bioavailability.
(3) Human data are central for the substantiation of health
claims on food products. Data from intervention studies
are generally given more weight than observational
data. Key considerations with respect to human studies
include choice of an appropriate study group, study
design and execution, with appropriate controls and
sufficient statistical power.
(4) When markers of a target end point are used, these mar-
kers should be biologically and methodologically valid.
(5) The target variable itself should change significantly and
the change should be biologically meaningful for the
target group. Also, the amount of food (constituent)
should be consistent with the intended consumption pat-
tern (i.e. the benefit should be achievable for the target
population with a realistic use of the food product).
Experience with the scientific evaluation and use of health
claims in recent years shows a clear need for further guidance
on what would be required to prove the efficacy of food
(constituents) and what evidence is needed to substantiate a
health claim. Key issues to be considered are the following:
(1) Well-designed randomised controlled trials (RCT) provide
the most persuasive evidence of efficacy, allowing strong
causal inferences. Other experimental studies, such as
observational studies, identify associations between
intake of food (constituent) and a beneficial effect on
health, although it may be difficult to distinguish whether
the observed difference in health status is due to differ-
ences in intake or to some other unrecognised (and
often unmeasured) factor. Appropriate study design and
statistical methods can be used to minimise the effects
of such confounding variables. However, as will be
discussed below, the use of RCT in evaluating clinical
treatments and pharmaceuticals (evidence-based medi-
cine) does not mean that this type of study is always
the most appropriate approach for the evaluation of
nutritional effects (evidence-based nutrition).
(2) Relationships between dietary factors and diseases are
likely to be extremely complex for both biological and
behavioural reasons. Types and amounts of food eaten
may be related to important non-dietary determinants of
health and diseases, such as genetics, environment and
lifestyle.
(3) The identification and validation of relevant markers or
marker patterns that reflect, or predict, potential benefits
or risks relating to a target function in the body or risk
factors for disease are important. There are, however,
differences in approaches taken by various scientific
bodies. It is important to assure the scientific robustness
of markers for disease risk and their relevance to the key
measure or target end point. There is also a need to focus
research on identification and validation of such markers.
(4) Studies should be performed according to current quality
standards and results should be reproducible. Guidelines
for the design, conduct and reporting of human interven-
tion studies are described elsewhere(14).
(5) As considering the total body of evidence is the most
appropriate way to judge substantiation of health
claims(1), a scientific framework is needed to assess the
strength, consistency, and biological plausibility of the
evidence. As will be discussed below, the findings from
several studies and their consistency should be weighed
and integrated.
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Building a scientific concept
Health claims require a systematic science-based evaluation of
the strength of the evidence to support a food–health relation-
ship. In order to build a scientific concept for this evaluation,
several steps have to be taken, which include considering
whether a claimed effect would imply a health benefit to a
specific target group, selecting appropriate study types,
target groups and markers or risk factors, considering the
biological plausibility of the claimed effect and last but not
the least weighing the totality of the available evidence.
Establishing benefit to health
Already at an early stage in the process of substantiating the
health effect of a food (constituent), it has to be considered
whether the effect to be claimed can reasonably be considered
as ‘beneficial to health’, i.e. whether the intake of a food (con-
stituent) results in a beneficial nutritional, physiological or
psychological effect. Health is not typically defined within
regulations and relates to the general condition of the body
or mind; it is often considered within the context of the
presence or absence of disease or impairments. The WHO
definition of 1946 states ‘health is a state of complete physical,
mental and social well-being and not merely the absence of
disease or infirmity’(15). ‘Benefit’, on the other hand, has
been defined, for example, in Europe by EFSA to be ‘the prob-
ability of a positive health effect and/or the probability of a
reduction of an adverse health effect in an organism, system
or (sub)population in reaction to exposure to an agent’(16).
With reference to European Union claims regulation, benefit
to health relates to the weighing of the totality of the available
scientific data. Depending on the outcome of this evaluation,
conclusions may be drawn that the probability of a change in
the dietary intake of a food (constituent) will result in a health
benefit and/or a health outcome, including a change in a dis-
ease end point. This could be, for example, a fatal or non-fatal
heart attack. The claimed effect must be clearly defined and
the applicant should provide a rationale derived from the
evidence as to why the claimed effect is considered nutrition-
ally or physiologically beneficial, the relevance to human
health and to what extent the effect has occurred. The use
and definitions of modal verbs (e.g. may, might, can or will)
or graphics could provide the opportunity to develop
appropriate qualifying language or symbols to reflect the
totality of the available data and the strength of the evidence.
A key word from the scientific assessment and regulatory
perspectives is ‘probability’. Examples from Europe of physio-
logical effects considered by EFSA to be ‘beneficial’ are the
maintenance of normal levels/functions such as blood choles-
terol/TAG, blood glucose, platelet aggregation, blood press-
ure, blood coagulation, energy-yielding metabolism and
tooth mineralisation. With respect to children’s development
and health, ‘beneficial’ has included normal visual develop-
ment, cognitive development, growth and development of
bone. Examples of risk factors accepted by EFSA include
loss of bone mineral density in postmenopausal women,
increased plaque acid (impacting on dental and oral health),
high blood cholesterol and an increase in potentially patho-
genic intestinal microorganisms(6).
In general, the extent of the causal relationship between the
maintenance of normal and enhanced functions and human
health should be demonstrated and should withstand scientific
scrutiny, at least showing that if the function is not maintained
within the normal range, human health can be affected. In
addition, as well-being and quality of life may be related
to physical states (‘health-related’), appropriate validated
questionnaires may be used as part of claim substantiation.
Representative study group: the concept of health
as a continuum
A beneficial health effect demonstrated in a certain study
population can be extrapolated to another, or wider, popu-
lation, given that the study population is representative of
the target population. As most health claims on foods are
intended for the ‘general public’, an important question con-
cerns what constitutes a representative study group. Aiming
to maintain health, claims target keeping an individual on
the healthy side of boundaries between health and disease.
As a continuum between health and disease often exists with-
out a strict boundary, it would be reasonable to find within the
‘general population’ some individuals with slightly elevated
blood pressure, slightly abnormal blood lipids, elevated mar-
kers of inflammation or mild liver impairment etc. Similarly,
within the ‘healthy’ general population, a significant pro-
portion of the population will be at risk of exhibiting certain
risk factors for diabetes, heart disease or other chronic dis-
eases and/or are overweight, but are otherwise going about
their daily lives. To demonstrate certain beneficial effects,
studies in a healthy population may not even be possible
and, depending on the function being considered, evidence
in slightly impaired individuals may represent an alternative.
The difficulty of clear demarcations between normal/
healthy and unhealthy/diseased may be reflected in some
examples. For instance, EFSA has accepted evidence for
claims on reducing gastrointestinal discomfort (in the general
population) evidenced in irritable bowel syndrome (i.e. in a
patient population)(17). In contrast, EFSA has not accepted
evidence for claims relating to maintenance of normal joints
(in the general population) evidenced by studies in those
with osteoarthritis (i.e. in a patient population), since
osteoarthritic cells/tissues may respond differently to interven-
tion(17). These opinions support that a case-by-case judgement
would be necessary. However, as consistent decisions on the
appropriateness of specific study groups are needed, it is
strongly advisable to develop a clear rationale for decision
making. We propose that the concept of health as a continuum
(as depicted in Fig. 1) be used.
The proposed model in Fig. 1 considers that the general
population, theoretically, comprises a range of individuals
from those without symptoms of disease and who are in opti-
mal health to those individuals who have an overt disease
status. The health status of the majority of individuals lies on
a continuum between these two extremes. In many cases
(particularly those of chronic diseases), a ‘disease status’
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develops as a continuum from a ‘normal’ to ‘diseased’ status.
The proposed model considers such a continuum with
health as a dynamic process. This includes sub-optimum func-
tions that can be improved. For health targets without estab-
lished markers, this model could be applied and evidence of
protection against a decline in health status would be con-
sidered as reducing the risk of disease (and/or maintaining
health). For most markers, a health benefit would be estab-
lished if the value of the marker moves towards an optimum,
i.e. towards the ‘perfect’ health part of the model. Equally, this
could be applied to a distribution of markers. A claim would
be substantiated by demonstrating a beneficial effect or main-
taining the healthy status of individuals for longer time periods
(for example, the reduced duration of an infection).
For health claims fitting this model, efficacy studies could
use participants with disease as a model rather than the
target population only.
In some cases, it may be difficult to demonstrate that
healthy people will become healthier when consuming a
specific food (constituent) with a putative health benefit.
Overcoming this difficulty may be possible by challenging
healthy individuals (e.g. exercise test) and observing recovery
or by considering a marginally unhealthy group. For example,
long-term maintenance of normal blood glucose concen-
trations is considered to be a beneficial physiological effect.
The effect of a food (constituent) on postprandial hypergly-
caemia in healthy participants could be considered. However,
to consider longer-term effects on blood glucose concen-
trations only in studies in those with impaired glucose
tolerance or those with type 2 diabetes mellitus, who are as
yet un-medicated, could generate appropriate evidence. Fur-
thermore, if there is no reason to expect interference between
the mechanisms of action between the drug(s) and the food
(constituent), then studies in medicated people can also be
used. Thus, populations in such studies used to support
health claims may need to comprise participants who could
be classed as healthy, marginally unhealthy or diseased.
Although demonstrating health benefits for the general
population is difficult, the use of well-defined subgroups
may represent an acceptable alternative.
Selecting appropriate study types and designs
Health claims require the establishment or building of a scien-
tific concept, followed by demonstration of effect often
through human intervention studies. The number and type
of studies required to demonstrate the claimed effect will
vary according to the targeted benefit and already available
knowledge/recognised scientific evidence. Also, the duration
of studies should be defined in accordance with the intended
beneficial effect and measures to be performed/markers to be
followed and the targeted claim.
In nutrition research, usually RCT are given greater weight
than (different types of) observational studies. Within the
category of observational studies, findings in prospective
cohort studies generally receive more weight than data from
case–control and cross-sectional studies(18). However, in the
case of disease risk reduction claims, such as in CHD, a
simple hierarchical approach to evidence on causal links
cannot rely on RCT(19). Given the complex nature of disease
processes over decades, reliance on the use of relatively
short RCT and risk factors/markers as primary sources of
evidence for disease risk-reduction claims is questionable.
Observational studies can provide evidence of an associ-
ation between consumption of a food (constituent) and
health status rather than conclusive proof of cause and
effect. However, properly designed and executed observa-
tional studies can provide a strong and consistent body of
scientific evidence, which includes information on low-
to-high quintiles of intake (i.e. an intake–effect relationship),
a statistically significant measure of relative risk of developing
the disease and true outcomes of the disease. For example, the
US FDA has approved a health claim on the relation between
intake of fruits and vegetables and a reduced risk of cancer(20).
Mechanistic studies, including both in vitro and in vivo
(animal) studies, can provide important information to sup-
port the health relationship. However, complete elucidation
of mechanisms should not be mandatory to support a claim
(assuming the claim is not describing a mechanistic aspect).
Indeed, for many pharmaceutical compounds (including
well-known paracetamol), precise mechanisms of action are
also not always known.
As various methodological problems and uncertainties are
inherent to all study types, including RCT, a hierarchy of
study types cannot be applied absolutely. Also, it should be
noted that methodological soundness overrides any hierarchy
in studies on human subjects, given that validity depends not
only on the appropriateness of the study type but also on
Healthy population
(i.e. 'without known disease')
'Perfect' health
Healthy
Impaired
Disease
Fig. 1. Concept of ‘health’ as a continuum. The model is proposed to provide
guidance on what effects/markers to consider when addressing physiological
effects of food constituents on health. Health is considered as a continuum
between perfect health (top) and disease (bottom) and reflects the general
population. ‘Perfect’ health is a theoretical ideal that cannot be reached.
Although usually the cut-off to disease is by convention set (unbroken hori-
zontal line), an arbitrary cut-off between healthy and diseased (i.e. ‘impaired’)
can be considered (broken horizontal line). Once the distribution of the
effect/marker has been defined in the population, upward movement of
the effect/marker (indicated by the upward arrow) would indicate lowering of
the proportion of disease/impairment or maintaining health for longer and
could be used to substantiate claims for the general population. For health
claims addressing a health effect/marker for which a continuum (for most
diseases) can be established, efficacy studies may use those with disease
as a model rather than the target population only. The grading of ‘grey’
reflects the increase of symptoms.
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the quality of its design, execution and analysis. The same
difficulties occur with comparison of different studies within
a meta-analysis(18). As will be discussed later, the totality of
the evidence needs to be assessed to determine the overall
strength of the scientific convictions being proposed.
Challenges of meta-analyses. Meta-analytical approaches,
with large sample sizes, are often superior to single-trial
approaches. For instance, meta-analyses for the validation of
surrogate end points have become a widely accepted and
applied method in oncology research. Without multi-trial
data, it is almost impossible to make any direct inference
about the association between the diet and the surrogate
and clinical end points, because one set of data cannot pro-
vide sufficient evidence of any association.
Doing a meta-analysis correctly demands expertise in both
the method and the substance, and hence almost always
requires collaboration between clinician(s) and an experi-
enced statistician. Models based on random effects are very
popular in meta-analyses, because they allow for inter-trial
heterogeneity. A challenging problem in the implementation
of a meta-analysis is to combine several studies in which
similar medical outcomes or covariates are captured and
considered. Furthermore, the meta-analysis needs to combine
studies that demonstrate homogeneity for dietary compo-
sition, that are well characterised and that are for a similar
specific claim. To obtain this, it is recommended that targeted
meta-analyses be undertaken within the specific context of a
specific claim.
It is impossible to say whether the results of a large RCT or
those of a meta-analysis of many smaller studies are more
likely to be close to the truth. Much depends on the details
of both the research studies and the analyses. When both
the trial and the meta-analysis appear to be of good quality,
however, we would tend to believe the results of the
large RCT.
Evidence-based nutrition v. evidence-based medicine.
Although it is important to apply high standards of scientific
investigation to the assessment of the impact of foods, the
complex nature of nutrition means that assessing the impact
of foods (constituents) may not be straightforward. Foods
(constituents) are clearly not developed to alter specific
body functions in order to prevent or treat diseases. Foods,
as well as health claims, are aimed at the general/healthy
population. Typically, in nutrition (evidence-based nutrition)
there are more than one (or a few) principal end points or out-
come measures, and the effects of food (constituents) may
rarely be evaluated relative to its absence. In most cases, nutri-
tional end points need to be measured over relatively long
periods of time. Nutrients and other substances that contribute
to nutritional or beneficial physiological effects tend to mani-
fest themselves in small differences over longer periods of
time. Nutrients work together, rather than in isolation, and
often their effects will not develop when intakes of other
dietary components are suboptimal. There is, in effect, rarely
a nutrient-free state against which the nutrient effects can be
compared. The dilemmas of focusing on pharmaceutical
approaches to evidence-based nutrition are highlighted by
Heaney(21) and Blumberg et al.(18).
The reliance on RCT to assess the impact of food (constitu-
ents) fails to address the limitations of this pharmaceutical
approach for nutrition and may explain, at least in part, the
heterogeneity of results from different research centres and
investigators and the different sources of evidence. For
example, in certain nutrition studies, controls (e.g. placebo
groups) may be difficult to define(13,18). Thus, when consider-
ing approaches to determine the efficacy of foods (constitu-
ents), it is important to differentiate between nutritional
practice (evidence-based nutrition) and drug practice
(evidence-based medicine).
Health claims relating to children. For claims relating to
consumption in children, evidence for substantiating the
claim should be generated in the target age group. However,
cases in which the physiology of a certain function of a
younger age group can be demonstrated to be equally appli-
cable to an older group, evidence generated in that older age
group would be sufficient. As with adults, studies in children
must be of high quality, but it must be realised that possibility
for standardisation of studies may be reduced when studying
children (as compared to adults) owing to ethical constraints,
e.g. blood sampling. Consideration may also be needed when
assessing study quality (v. feasibility) of such scientific evi-
dence. For example, cross-over trials may not be possible
due to physiological changes related to growth/development
in the participants.
Choice of risk factors/markers
Valid (bio)markers are essential for substantiating claims or
messages using a combination of intervention and observa-
tional studies together with appropriate analyses. However,
it is important to differentiate between markers for disease
(with regard to drugs) and markers for health/risk of disease
(with regard to foods). For the substantiation of function
claims, a beneficial nutritional, physiological, psychological
(e.g. cognitive/mental performance) or behavioural effect
needs to be demonstrated. A marker (or set of markers) for
a function is a measurable parameter that is indicative of the
state of a particular function and thus helps to determine the
effect of a food on a function and the state of health of an
individual. According to PASSCLAIM, markers should be
biologically valid, in that they have a known relationship to
the final clinical outcome, and their variability within the
target population must be known(1). Methodologies to
measure the marker would need to be developed across a
range of values or at a threshold value corresponding to the
healthy and normal function of organs/tissues. For example,
flow-mediated dilation is a recognised indicator of blood
vessel functionality and can predict whether there is (or is
not) dysfunction.
It is relevant to note that the EFSA definition of a ‘reduction
of disease risk’ claim implicates that it is not a reduction of the
risk for developing a disease that can be claimed, but only the
reduction of a risk factor for the disease. Defining a suitable
risk factor for disease may be complicated. According to the
National Institutes of Health(22), a risk factor increases the like-
lihood of development of a disease rather than predicting it.
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According to EFSA(23), a ‘risk factor is a factor associated with
the risk of a disease that may serve as a predictor for the devel-
opment of that disease’. This definition is rather general. Most
risk factors are correlational and are not necessarily causal.
The relationship of a risk factor to the development of a dis-
ease should be biologically plausible. Furthermore, decreasing
a risk factor should also be associated with a reduction of the
risk for the disease. In certain cases, a surrogate end point (a
biomarker intended to substitute for a clinical end point that
should predict clinical benefit or harm or lack of both) can
be used. There are also cases in which a reduction in the inci-
dence of specific diseases can be used to support a more gen-
eral claim, which is related to the reduction of a risk factor. For
example, if it is adequately demonstrated that consumption of
a food (constituent) decreases specific gastrointestinal or res-
piratory tract infections, this can help to define a risk factor
that correlates with ‘resistance to infections’ or ‘immune
function’.
The choice of appropriate risk factors and biomarkers
depends on the objective of a particular study. Markers
and/or risk factors can be used at different biological levels
(i.e. at the cellular, organ, individual participants or at a
population level). The choice of biomarker(s) should be vali-
dated with agreement amongst independent experts in the
field based on previous research using different scientific
approaches (in vitro, animal, intervention studies in healthy/
pre-symptomatic/unhealthy volunteers or cohort studies).
Established physiological risk factors, all of which are cur-
rently regarded as disease related, include the following:
raised blood pressure, raised plasma insulin, raised fasting glu-
cose, raised plasma total cholesterol and LDL, raised LDL:HDL
ratio or loss of bone mineral density. Emerging risk factors
include ghrelin levels (for obesity), faecal calprotectin
(for inflammatory bowel disease) and adenomatous polyps
(for colorectal cancer). These risk factors are based on phar-
macological and disease responses, and are not necessarily
indicators of the normal, robust, homeostatic mechanisms
and state of health and resistance to disease. When other
risk factors are proposed, the applicant is required to provide
scientific justification. As stated later in the final recommen-
dations of this paper, validating/establishing such risk factors
should be a research priority for industry and academia.
In certain cases, a set of markers is more convincing than a
single biomarker. One example is the guidelines for the global
assessment of symptom relief in irritable bowel syndrome
trials(24). In this case, the composite scores of frequency of
digestive complaints is the sum of frequency of four individual
digestive complaints (i.e. abdominal pain/discomfort, bloat-
ing, flatulence/passage of gas and borborygmi/rumbling
stomach) and these can be evaluated using a five-point scale
ranging from 0 (‘never’) to 4 (‘every day of the week’). Key
outcomes can also be based on questionnaires assessing
either a specific condition or making a health or nutritional
assessment. In recent years, the use of questionnaires has
gained greater recognition by experts in the field of digestive
health. A questionnaire must be developed for use in the
population in which the effect of a food (consistent) will be
demonstrated. The method used for the development of the
questionnaire must follow general recommendations for the
development of participant-reported outcomes and accepted
methods in the area of research. The validation of the ques-
tionnaire must comprise the validity of the concept measured
in the target population, the tool of measuring (e.g. Likert
scale or visual analog scale), the reference period of the
measure (e.g. daily, weekly, monthly), as well as the
method of measuring (e.g. method of presentating questions,
instruction given to participants answering the questions). The
sensitivity of the questionnaire should be supported by its
ability to discriminate populations with different levels of the
concept measured. The description of the factors that may
influence the measures (i.e. confounding factors) is an import-
ant point for the use of the questionnaire in intervention trials.
However, in several areas of research, no validated physio-
logical markers exist. With the exception of well-established
risk factors, in Europe a case-by-case approach is taken by
EFSA to assess the extent to which the reduction of a risk
factor is beneficial in the context of a given disease risk
reduction claim(17). Reduction of risk factors/markers from
human intervention studies appear to be given greatest pri-
ority. For example, EFSA(17) considered that ‘dietary beha-
viour’ (e.g. diets with low content of a specific category of
foods) would not be acceptable as a risk factor in this context
(of ‘reduction of disease risk’) as the beneficial alteration of
the risk factor (increased consumption of a specific category
of foods) would not be considered as a beneficial physiologi-
cal effect, as required by the Regulation (1924/2006). How-
ever, modifiable behavioural risk factors, such as diet, are
relevant to underpin health claims, especially when the
claim has the potential to enhance consumers’ knowledge of
healthy eating patterns and when the health claim comp-
lements well-established dietary recommendations(23).
For the substantiation of claims in children, apart from
growth and development, food (constituents) may also aim
to affect acute and/or longer-term functions. For example,
prolonged modulation of nutrients in early life may influence
brain development in a manner that permanently affects visual
function or intelligence quotient of children. On the other
hand, cognitive functions such as reaction time, memory and
information processing speed, attention and ‘normal activity’
may be variable and influenced acutely by nutrients and
other environmental factors. If food (constituents) acutely
modulated such functions, then their effect would be related
to the acute intake rather than sustained intakes and perma-
nent stimulation. Putative long-term effects such as improved
academic achievement could also be considered, although
influences from environment and lifestyle variables are
difficult to control.
An appropriate statistical procedure needs to be used when
multiple exposures are examined using a ‘multiple compari-
son’ approach. The P value used for statistical significance
should be adjusted according to the number of variables
examined. These techniques generally require a stronger
level of evidence to be observed in order for an individual
comparison to be deemed ‘statistically significant’, so as to
compensate for the number of inferences being made. Mul-
tiple testing corrections refer to re-calculating probabilities
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obtained from a statistical test that was repeated multiple
times. The use of post hoc analyses or looking at the data
(after the study has concluded) for patterns that were not
specified a priori also has some limitations. Each time a pat-
tern in the data is being considered, a statistical test is effec-
tively being performed. This greatly inflates the total number
of statistical tests used and necessitates the use of multiple test-
ing procedures to compensate for this. Results of post hoc
analysis should be explicitly labelled as such in reports and
publications.
Biomarker patterns in relation to homeostatic adaptability.
There are relatively few validated biomarkers and risk factors
applied to foods. Therefore, the identification of further rel-
evant marker(s) to measure food functionality in the human
body is one of the most important challenges within nutrition
research today. The key challenges facing researchers are:
first, identifying the link between a marker (or a set of mar-
kers) and a function or between marker(s) and the risk of a
disease; second, it is important to identify a method to
measure such marker(s); third, to observe the impact of a par-
ticular food on such marker(s) and hence its impact on health.
On the basis of the principle that nutrition primarily aims to
maintain or possibly improve health, new methods and
models are currently being developed that better take into
account the complexity and balance of homeostatic mechan-
isms. These models are based on dynamic processes instead
of single end points. Recent advances in genomics and
systems biology enable researchers to measure and model
biomarker profiles and to translate these into dynamic
processes. On the basis of the classical principles of
homeostasis and biological evolution, it is proposed that the
term ‘health’ be defined as ‘the ability to adapt’ to internal
and external stimuli. In case of chronic pathology or slow-
developing pathologies, it can be said that there is an adap-
tation, as the individual can live with it for very long period
of time, even without medication. However, this adaptation
does not mean this individual would be considered to be a
healthy person. Thus, as illustrated in Fig. 2, the individual’s
homeostasis acts to maintain balance within biological pro-
cesses and is reflected by clusters of functional biomarkers
that are kept within a certain range.
Clusters of biomarkers that reflect essential processes, such
as inflammation or oxidative stress, can be used to construct a
theoretical multi-dimensional ‘health space’(25). These models
can be used to illustrate effects of nutritional intervention on
homeostatic balances in individuals. A biomarker approach
may be used to detect early signs of homeostatic disturbance,
as observed, for example, at onset of disease. Indeed, adaptive
states, such as a chronically increased inflammatory status,
clusters of cardiovascular risk factors and/or specific changes
in metabolic fluxes, may be used as indicators of suboptimal
health well before there is any clinical sign of disease. It is
recognised that large inter-individual differences in ‘normal’
biological processes values exist, which give rise to an
added complexity.
A broader and probably more predictive indication of
health status is obtained by measuring the robustness (adapta-
bility) of the processes of homeostasis in an individual. It
is well-accepted that when an organism is challenged
(i.e. when its system is disturbed) various compensatory
Early biomarkers of
chronic disease
Late biomarkers of
disease
Nutrition
'Chronic
disease'
PharmaNutrition
'Healthy'
Biomarkers of
homeostatic adaptability
Time
Episode of
acute/resolved
cured disease
Fig. 2. Biomarker patterns in relation to homeostatic adaptability. Schematic depiction of the concept of physiological balance and the significance of biomarker
patterns for various stages of development in time from normality (homeostasis), via dysfunction, to chronic disease. An organism maintains homeostasis for as
long as possible by changes in its metabolic pathway dynamics. Nutrition aims to support this homeostasis. Chronic disease develops when an organism (individ-
ual) is no longer able to maintain homeostatic processes within a certain limit and may require intervention. A disease process can either further deteriorate or
stabilise at a new homeostatic state.
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mechanisms are used so that homeostasis is maintained for as
long as possible. Challenge tests may be used in nutrition and
health research to measure this adaptability, and such tests
include variations of standardised oral glucose and lipid toler-
ance tests, organ function tests, infection challenge tests, exer-
cise stress and psychological stress challenges. When
combined with newer bioanalytical and statistical tools, such
standardised tests (such as the oral glucose tolerance test)
may be greatly enhanced, making them particularly useful to
test health-improving effects of nutritional products.
Biological plausibility
In the context of nutrition and health claims, biological plausi-
bility can be defined as the probability that, or the extent to
which, a causal effect is demonstrated between the food (con-
stituent) and the claimed physiological or psychological effect
in human subjects, which is consistent with existing biological
knowledge. From a regulatory point of view, the weight that is
given to biological plausibility in claims substantiation is not
consistent across the globe. EFSA has indicated that a rationale
or evidence on biological plausibility of the claimed effect
should be provided to support the substantiation of the
claim(26). The US FDA, however, states that animal and
in vitro studies can be used to generate hypotheses, investi-
gate biological plausibility of hypotheses or explore mechan-
ism(s) of action of a specific food (constituent) through
controlled animal diets; however, these studies do not provide
information from which scientific conclusions can be drawn(9)
Also, Health Canada indicates that, if desired, non-human
studies may be used to support the discussion on biological
plausibility and that this is optional(27). Biological plausibility
is one of the most difficult causation criteria. In nutrition
science, the biological evidence is collected from animal
models, in vitro cell systems and human metabolic and inter-
vention studies. There is as yet no consensus on the relative
importance of each of these types of evidence, and decisions
on usefulness tend to be subjective at present, especially with
regard to causal inference. Biological plausibility is closely
related to understanding the mechanism of action for the food
(constituent) of interest. Thus, when assessing biological
plausibility, the existence and/or relevance of possible multiple
biological functions of the food (constituent) needs to be con-
sidered. Furthermore, with the complex inter-relationships of
nutrients in the diet coupled with the potential for metabolic
nutrient–nutrient interactions, a simplistic approach can be
misleading. Also, the co-existence of constituents in the same
foods and in associated foods provides an opportunity for
multiple mechanisms. Consequently, biological plausibility
has to be established on a case-by-case basis.
Weighing the totality of the evidence
Health claims require a high standard of evidence. PASSCLAIM
established a robust standard with which it is possible to com-
pare the quality of state of the art nutritional scientific data
submitted in support of health claims and provide a basis
for the harmonisation of the scientific evaluation and approval
of such claims(1). Also, the requirement for assessing the total-
ity of the scientific data and weighing the evidence is built into
current legislative regulations. The assessment of each specific
food–health relationship that forms the basis of the claim is
therefore based on a scientific judgement on the extent to
which a cause and effect relationship is established by
taking into account the nature and quality of different sources
of evidence. In each case, the evidence is weighed with
respect to its overall strength, consistency and biological
plausibility (i.e. likelihood), but currently a grade of evidence
is not assigned. In Europe, for instance, the outcome of each
assessment has one of three conclusions: (1) a cause and
effect relationship has been established between the con-
sumption of the food (constituent) and the claimed effect
(i.e. the claim is substantiated by generally accepted scientific
evidence); (2) the evidence provided is insufficient to establish
a cause and effect relationship between the consumption of
the food (constituent) and the claimed effect (i.e. cause and
effect is not conclusive because the evidence is emerging
and/or conflicting, and the claim is thus not substantiated by
‘generally accepted scientific evidence’); (3) a cause and
effect relationship has not been established between the con-
sumption of the food (constituent) and the claimed effect
(i.e there is no or, at most, limited scientific evidence, and
thus the claim is not supported by ‘generally accepted
scientific evidence’)(17). The authors acknowledge the import-
ance of understanding what ‘generally accepted scientific
evidence’ entails.
PASSCLAIM considered both the evaluation of the totality of
the data and weighing of the evidence to be important in view
of different interpretations of conflicting evidence and the
potential variation in quality amongst individual studies. Not
all research has been, or will be, carried out to the highest
standard, or even to a common standard. This may, in part,
be due to the complexities of research in human subjects
and also because data in support of a claim may have been
taken from studies that had a different primary objective.
Despite potential limitations in the research base, there may
be complementarity between individually incomplete studies
that support an assessment of the totality of the evidence to
substantiate a claim, for example, using a meta-analysis.
Conversely, a review of all the studies taken together may
reveal evidential inconsistencies that are not apparent from
the review of a single study in isolation(1). PASSCLAIM also
stated that any template needs to be applied intelligently
and sensitively to the existing and potential claims on a
case-by-case basis, with respect to both gaps in knowledge
and to the development of new knowledge. Although PASS-
CLAIM provided a scientific framework to facilitate the assess-
ment of scientific support for claims on foods, it did not
specifically address weighing of the evidence. However, it
was later emphasised that the evaluation process should be
transparent and that the grading of evidence into categories,
including ‘convincing’, ‘probable’, ‘possible’ and ‘insufficient’,
could be considered useful in scientific evaluations and to
monitor the development of the scientific substantiation for
the claim(28).
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The development of a scientific framework for weighing the
totality of the available data and the determination of the
extent to which a cause and effect relationship is demon-
strated are both scientifically justified. However, there is cur-
rently no consensus about how the beneficial associations
between foods (constituents) and health can be tested and
established, and indeed whether the requirement for conclus-
ive evidence of cause and effect is proportionate and achiev-
able in nutrition science. Key questions relate to what
constitutes the totality of the evidence and by what means it
should be developed and weighed. Although some guidelines
have been provided, there is still a need for a clear framework
for the assessment of the strength of the evidence, otherwise
applicants for a health claim will not be clear on the research
programs they will need to construct to substantiate a claim.
It is necessary to have a transparent framework for comment-
ing on the nature and quality of the totality of the data and for
weighing the evidence in order to allow independent experts
to judge about the scientific evidence of a health claim
submitted by an applicant.
(Inter)national organisations have used various systems to
assess the level of evidence from different types of studies.
One common approach is the distinction between different
levels of evidence. This classification of the evidence into
categories (e.g. ‘convincing’, ‘probable’, ‘possible’ and ‘insuffi-
cient’) has proven to be a useful tool in scientific evaluations.
For instance, the WHO(29) and the World Cancer Research
Fund(30) have published comprehensive and rigorous evalu-
ations of the strength and consistency of evidence for the
relationship between certain nutrition factors and different
chronic diseases, with judgments characterised as being ‘con-
vincing’ or ‘probable’ considered strong enough to justify
population goals and personal recommendations(29,30). In
the recent EFSA scientific opinion on establishing food-
based dietary guidelines(31), the identification of diet–health
relationships was described using the same terminology,
namely, convincing evidence, probable evidence, possible
evidence and insufficient evidence. Likewise, the EFSA consul-
tation paper on guidance on human health risk–benefit
assessment of foods(16) defines ‘benefit’ as the probability of
positive health effects and/or the probability of a reduction
of an adverse health effect. Other researchers(32) have
proposed similar approaches for assessing the strength of
the evidence and identifying the criteria for the use of the
terms strong, moderate or weak. Although the classification
could be criticised for being arbitrary, this framework illus-
trates that it is possible to assess the extent of the evidence
of causation and to compare the consistency of relative risks
Epidemiological data:
consistent results
Single large
human study
Epidemiological data:
contradictory results
In vitro or animal
(laboratory) data
only
Small uncontrolled
human studies
Single small human
study
Multiple small
human studies
Meta-analyses
– supportive laboratory data
Reported
Body of consistent, relevant evidence
from well-designed human study and/or
epidemiological and laboratory studies.
Weight of evidence supportive
Critical reviews
by experts
Evidence accepted
by scientific bodies
or independent
expert bodies as
basis for public
health messages
– supportive epidemiological data
– contradictory epidemiological data
– supportive laboratory data
– contradictory laboratory data
Reviews by
independent expert(s)
– difficulty in measuring substance
– biological plausibility and
   consistent laboratory data
– contradictory laboratory data
Significant scientific agreement
Consensus
Emerging evidence
– consistent results with
   flawed designs
– consistent results with
   good designs
– contradictory results
   with good designs
Fig. 3. Graphical representation for weighing of the evidence on a case-by-case basis in support of a health claim. †Adapted from Richardson et al.(33). The
arrows reflect the fact that the totality of the evidence is made up of different sources of scientific data, and that each health relationship and claim must be
assessed on a case-by-case basis to reflect the strength, consistency and coherence of the information. The graphical representation also reflects the scientific
method, in that individual study results can be inconsistent, but as the science evolves, consensus may evolve, which allows the balance of probabilities for the
scientific link between a food (constituent) and a health benefit to be assessed(33).
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from cohort studies with outcomes from RCT. The findings
support the strategy of investigating dietary patterns in
cohort studies and RCT, especially for common and complex
multi-causal chronic diseases such as CHD.
Clearly, the concepts developed by PASSCLAIM(1), WHO(29),
the World Cancer Research Fund(30) and EFSA(31) could be
used further to underpin the assessment of the totality of the
available data and, in particular, the weight of the evidence
such as that illustrated in Fig. 3 on a case-by-case basis.
Conclusions and key recommendations
The identification of a suitable scientific framework for
the weighing of evidence is now critical to embrace ‘state
of the art’ nutrition science, to stimulate future academic
research, to promote product innovation and to communicate
accurate and truthful nutrition and health messages to
the public.
In conclusion, the substantiation of a health claim needs
to take place on a case-by-case basis. As a first step to a
substantiation process, a strategy is needed to ensure scien-
tific consensus, which includes input from independent
scientific experts and, if possible, regulatory authorities.
Such a strategy includes elements such as the benefit
(in the targeted claim) to health, considerations concerning
what constitutes the ‘healthy population model’, selection
of the appropriate study target groups’ considerations and
decisions on the extent to which the mechanism of action
will be established and which (bio)markers and risk factors
will be used and (if necessary) validated, type, design and
number of studies enabling demonstration of reproducibility
of the claimed effect. All these elements have been con-
sidered in this paper. In executing the substantiation strat-
egy, any deviations should be clearly explained and
documented. Where such a deviation is significant, it is
recommended that scientific consensus is re-established.
The chosen strategy and its execution should be sub-
sequently included in the scientific dossier that is submitted
to substantiate the targeted health claim.
In addition, it is recommended that:
(1) Further discussion is needed on the basis for accepting
whether a demonstrated effect can be considered as
beneficial to health.
(2) A suitable scientific framework should be agreed that
addresses the relationship between intervention andobser-
vational studies, taking account of characteristics of the
food constituent (or nutrient), quality of the studies, appro-
priateness of study populations, confounding (in observa-
tional studies) and design of the intervention studies.
(3) A suitable scientific framework for the weighing of
evidence should be agreed.
(4) Validating/establishing risk factors should be adopted
as a future research priority. Expert groups should be
convened to provide consensus on the level of accept-
ability of emerging risk factors.
(5) A continuum of health approach should be applied
where applicable.
(6) Models based on measuring the adaptability of homeo-
static processes should be further developed and evalu-
ated, preferably by international research consortia in
which industry and academic groups work together.
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